StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30133% above fair value
$162.18−0.60 (-0.37%)

Close on Nov 17, 2026Market cap $10.37BP/E –Yield –

Repligen ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Repligen's ebitda for the twelve months ending Sep 30, 2026 was $96.14M, up 23.3% year over year. For fiscal 2025 it was $133.91M, up 287.5% from the year before. Over ten years it grew 22.0% a year on average. The highest annual figure on record is $275.66M in fiscal 2022.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025$133.91M+287.5%
FY2024Dec 31, 2024$34.56M-70.3%
FY2023Dec 31, 2023$116.26M-57.8%
FY2022Dec 31, 2022$275.66M+34.0%
FY2021Dec 31, 2021$205.70M+112.3%
FY2020Dec 31, 2020$96.89M+70.1%
FY2019Dec 31, 2019$56.95M+36.4%
FY2018Dec 31, 2018$41.77M+70.4%
FY2017Dec 31, 2017$24.51M+15.0%
FY2016Dec 31, 2016$21.31M+16.1%
FY2015Dec 31, 2015$18.36M+24.8%
FY2014Dec 31, 2014$14.71M-43.4%
FY2013Dec 31, 2013$25.99M+1898.3%
FY2011Mar 31, 2011$1.30M–
FY2010Mar 31, 2010-$4.39M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$10.42M-128.3%
Q2 FY2026Jun 30, 2026$33.04M-2.8%
Q1 FY2026Mar 31, 2026$35.70M+41.2%
Q4 FY2025Dec 31, 2025$37.82M–
Q3 FY2025Sep 30, 2025$36.83M+284.1%
Q2 FY2025Jun 30, 2025$33.98M+51.4%
Q1 FY2025Mar 31, 2025$25.28M+22.4%
Q4 FY2024Dec 31, 2024-$18.13M-166.8%
Q3 FY2024Sep 30, 2024$9.59M-60.9%
Q2 FY2024Jun 30, 2024$22.44M-36.6%
Q1 FY2024Mar 31, 2024$20.66M-29.3%
Q4 FY2023Dec 31, 2023$27.13M-57.1%
Q3 FY2023Sep 30, 2023$24.51M-62.5%
Q2 FY2023Jun 30, 2023$35.38M-53.0%
Q1 FY2023Mar 31, 2023$29.23M-59.3%
Q4 FY2022Dec 31, 2022$63.22M+30.5%
Q3 FY2022Sep 30, 2022$65.34M+18.4%
Q2 FY2022Jun 30, 2022$75.27M+31.5%
Q1 FY2022Mar 31, 2022$71.83M+60.2%
Q4 FY2021Dec 31, 2021$48.45M+94.5%
Q3 FY2021Sep 30, 2021$55.20M+99.5%
Q2 FY2021Jun 30, 2021$57.22M+119.9%
Q1 FY2021Mar 31, 2021$44.83M+145.0%
Q4 FY2020Dec 31, 2020$24.91M+108.0%
Q3 FY2020Sep 30, 2020$27.67M+102.0%
Q2 FY2020Jun 30, 2020$26.02M+63.7%
Q1 FY2020Mar 31, 2020$18.30M+18.9%
Q4 FY2019Dec 31, 2019$11.97M+1.0%
Q3 FY2019Sep 30, 2019$13.70M+16.4%
Q2 FY2019Jun 30, 2019$15.89M+93.7%
Q1 FY2019Mar 31, 2019$15.38M+54.8%
Q4 FY2018Dec 31, 2018$11.86M+60.3%
Q3 FY2018Sep 30, 2018$11.77M+337.4%
Q2 FY2018Jun 30, 2018$8.21M+14.5%
Q1 FY2018Mar 31, 2018$9.94M+36.9%
Q4 FY2017Dec 31, 2017$7.40M+68.3%
Q3 FY2017Sep 30, 2017$2.69M–
Q2 FY2017Jun 30, 2017$7.17M–
Q1 FY2017Mar 31, 2017$7.26M–
Q4 FY2016Dec 31, 2016$4.40M–

More Repligen figures

See a number that looks wrong?